Verdeca gets US FDA OK for anti-stress protein
The Verdeca joint venture between US agricultural biotechnology company Arcadia Biosciences (Davis, California) and Argentine soybean development consortium Bioceres (Rosario) has received notification from the US FDA that it has completed the early food safety evaluation (EFSE) process for the HAHB4 protein responsible for Verdeca's HB4 stress tolerance trait. Completion of this review is a major milestone in the development of commercial soybean seed products based on the trait as well as the development of HB4-based products in other crops, the companies point out. "Soybean seed products based on the HB4 stress tolerance trait are in the latter stages of development and completion of the EFSE process is a very strong and positive signal about safety," says Arcadia president and CEO Eric Rey. Last month, Arcadia, Bioceres and Brazilian company Tropical Melhoramento e Genética agreed to develop soybean varieties based on the HB4 trait, which was approved in Argentina in April.